27
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination

      research-article
      1 , 2 , 3 , 4 , 5 , 4 , 2 , 1 , 1 , 1 , 1 , 1 , 6 , 7 , 4 , 4 , 4 , 4 , 4 , 4 , 1 , 8 , 9 , 10 , 11 , 12 , 12 , 2 , 13 , 8 , 2 , 13 , 4 , 13 , 3 , 5 , 10 , 14 , 4 , 1 , 2 , 6 , 13
      Nature medicine

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Molecular understanding of serological immunity to influenza has been confounded by the complexity of the polyclonal antibody response in humans. Here we used high-resolution proteomics analysis of immunoglobulin (referred to as Ig-seq) coupled with high-throughput sequencing of transcripts encoding B cell receptors (BCR-seq) to quantitatively determine the antibody repertoire at the individual clonotype level in the sera of young adults before and after vaccination with trivalent seasonal influenza vaccine. The serum repertoire comprised between 40 and 147 clonotypes that were specific to each of the three monovalent components of the trivalent influenza vaccine, with boosted pre-existing clonotypes accounting for ~60% of the response. An unexpectedly high fraction of serum antibodies recognized both the H1 and H3 monovalent vaccines. Recombinant versions of these H1 + H3 cross-reactive antibodies showed broad binding to hemagglutinins (HAs) from previously circulating virus strains; several of these antibodies, which were prevalent in the serum of multiple donors, recognized the same conserved epitope in the HA head domain. Although the HA-head-specific H1 + H3 antibodies did not show neutralization activity in vitro, they protected mice against infection with the H1N1 and H3N2 virus strains when administered before or after challenge. Collectively, our data reveal unanticipated insights regarding the serological response to influenza vaccination and raise questions about the added benefits of using a quadrivalent vaccine instead of a trivalent vaccine.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

          The intranasal inoculation of volunteers with living partially attenuated strains of influenza A and B viruses offers a new opportunity to determine the protective effect of serum haemagglutin-inhibiting antibody against a strictly homologous virus, under conditions where the time and dosage of the infective challenge can be controlled, the scoring of proven infections can be more precise and higher rates of infection can be achieved than in most natural epidemics.In 1032 adult volunteers, whose serum HI antibody titre was determined immediately before virus challenge, there was a consistent inverse quantitative relationship between the HI titre and the likelihood of infection. The PD 50 (50% protective dose) of HI antibody was 1/18-1/36, but an unusual finding was that volunteers with no detectable pre-challenge antibody often seem to be less susceptible to infection than those with pre-challenge antibody in low titre.In one group of volunteers challenged with an influenza B strain there was no evidence that pre-challenge antibody titres against viral neuraminidase had any significant protective effect against challenge infection.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The promise and challenge of high-throughput sequencing of the antibody repertoire

            Georgiou and colleagues discuss rapidly evolving methods for high-throughput sequencing of the antibody repertoire, and how the resulting data may be applied to answer basic and translational research questions.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Advances in the development of influenza virus vaccines.

              Influenza virus infections are a major public health concern and cause significant morbidity and mortality worldwide. Current influenza virus vaccines are an effective countermeasure against infection but need to be reformulated almost every year owing to antigenic drift. Furthermore, these vaccines do not protect against novel pandemic strains, and the timely production of pandemic vaccines remains problematic because of the limitations of current technology. Several improvements have been made recently to enhance immune protection induced by seasonal and pandemic vaccines, and to speed up production in case of a pandemic. Importantly, vaccine constructs that induce broad or even universal influenza virus protection are currently in preclinical and clinical development.
                Bookmark

                Author and article information

                Journal
                9502015
                8791
                Nat Med
                Nat. Med.
                Nature medicine
                1078-8956
                1546-170X
                1 February 2017
                07 November 2016
                December 2016
                10 February 2017
                : 22
                : 12
                : 1456-1464
                Affiliations
                [1 ]Department of Chemical Engineering, University of Texas at Austin, Austin, Texas, USA
                [2 ]Center for Systems and Synthetic Biology, University of Texas at Austin, Austin, Texas, USA
                [3 ]Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
                [4 ]Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
                [5 ]Department of Bioengineering, Stanford University, Stanford, California, USA
                [6 ]Department of Biomedical Engineering, University of Texas at Austin, Austin, Texas, USA
                [7 ]Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA
                [8 ]Department of Medicine, Section of Rheumatology, Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, Illinois, USA
                [9 ]Department of Pediatrics, Stanford University, Stanford, California, USA
                [10 ]Howard Hughes Medical Institute, Stanford University, Stanford, California, USA
                [11 ]Department of Microbiology and Immunology, Stanford University, Stanford, California, USA
                [12 ]Center for Vaccines and Immunology, Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA
                [13 ]Department of Molecular Biosciences, University of Texas at Austin, Austin, Texas, USA
                [14 ]Department of Applied Physics, Stanford University, Stanford, California, USA
                Author notes
                Correspondence should be addressed to G.G. ( gg@ 123456che.utexas.edu )
                [15]

                Present addresses: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA (B.J.D.); Antibody Engineering Department, Genentech, Inc., South San Francisco, California, USA (K.H.H.); Division of Infectious Diseases, SRI International, Harrisonburg, Virginia, USA (L.I.P.).

                Article
                PMC5301914 PMC5301914 5301914 nihpa846495
                10.1038/nm.4224
                5301914
                27820605
                0e5ef183-a552-404b-870c-7938d720cdf9

                Reprints and permissions information is available online at http://www.nature.com/reprints/index.html.

                History
                Categories
                Article

                Comments

                Comment on this article